Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05776875 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05776875 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 3 participants.
The verdict
NCT05776875, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing the response to immune therapy not just locally, but systemically. In addition, there is now positive data with immune therapy in advanced HCC, there is renewed interest in the combination of local therapy and systemic therapy in Barcelona Clinic Liver Clinic B (BCLC B) patients with systemic therapies other than sorafenib. Based on this data, the investigators plan to examine the atezolizumab and bevacizumab combination with Transarterial Chemoembolization (TACE) in patients with BCLC B HCC.
Interventions
- DRUG Bevacizumab
- COMBINATION_PRODUCT Transarterial chemoembolization
- DRUG Atezolizumab Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05776875
The ClinicalTrials.gov registry entry for NCT05776875 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT05776875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05776875 about?
NCT05776875 is a clinical study titled "Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC". There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing the response to immune therapy not just locally, but systemically. In add...
What is the current status of trial NCT05776875?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2023-06-07. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT05776875?
The interventions under investigation include: Bevacizumab (DRUG), Transarterial chemoembolization (COMBINATION_PRODUCT), Atezolizumab Injection (DRUG).
Who is sponsoring clinical trial NCT05776875?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.